Chicago Headquartered Tempus, pioneering AI-enabled precision medicine, has entered a third strategic collaboration with pharma giant Pfizer, aiming to gather insights that will inform novel drug discovery and development in oncology with higher precision.
Tempus announced the agreement of the multi-year strategic collaboration on Tuesday. The companies will be working together to further AI and machine learning-driven efforts in therapeutic development.
Uncovering insights to power therapeutic development in oncology with AI-enabled platform and Data Library
Through this collaboration, Pfizer will have access to the Tempus AI-enabled platform and its library of de-identified, multimodal data to uncover insights that will power therapeutic development in oncology. Pfizer will also have access to Tempus’ broad range of capabilities that support therapeutic R&D to advance its own oncology portfolio, including AI-driven companion diagnostic offerings and Tempus’ clinical trial matching program, TIME, that rapidly activates studies for patients in communities across the country.
Eric Lefkofsky, Founder and CEO of Tempus stated:
“Pfizer shares our commitment to bringing novel treatments to patients faster, and we look forward to working together to usher in the next generation of oncology therapeutics.”
“This is the third strategic collaboration Tempus has established with a global pharmaceutical leader in the last year, as we believe that combining our technological capabilities with pharma’s deep R&D expertise will get us much closer in realizing the full potential of precision medicine.”
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The aim is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.
In October 2022, Tempus also announced an expansion of its GSK collaboration in Precision Medicine to Accelerate R&D. Through accessing Tempus’ AI-enabled platform, including its library of de-identified patient data, GSK will focus on optimising clinical trial design, speeding up enrolment, and identifying drug targets.
For more information, visit tempus.com.